^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PODXL overexpression

    i
    Other names: Podxl, Podocalyxin, PCLP-1
    Entrez ID:
    5420
    over1year
    Tumor endothelium-derived PODXL correlates with immunosuppressive microenvironment and poor prognosis in cervical cancer patients receiving radiotherapy or chemoradiotherapy. (PubMed, Biomark Res)
    In addition, PODXL over-expression was also found to be negatively associated with immune response and indicated poor survival in bulk RNA sequencing data of CC treated with radiotherapy or chemoradiotherapy. These results underscore the role of PODXL in CC, suggesting it as a promising target and prognostic marker for patients treated with radiotherapy or chemoradiotherapy.
    Journal
    |
    PODXL (Podocalyxin)
    |
    PODXL overexpression
    over1year
    Has_circ_0002360 promotes the progression of lung adenocarcinoma by activating miR-762 and regulating PODXL expression. (PubMed, Transl Cancer Res)
    In general, the has_circ_0002360/miR-762/PODXL axis affected the progress of LAC. The results of our study identified has_circ_0002360 as a novel oncogenic RNA in LAC.
    Journal
    |
    PODXL (Podocalyxin)
    |
    PODXL overexpression
    2years
    A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts. (PubMed, Int J Mol Sci)
    In the PDAC xenograft model, both PcMab-6-mG-f and humPcMab-6-f exhibited potent antitumor effects. These results indicated that humPcMab-6-f could apply to antibody-based therapy against PODXL-expressing pancreatic cancers.
    Journal
    |
    PODXL (Podocalyxin)
    |
    PODXL overexpression
    4years
    RNA-binding proteins RBM-HuR, RBM3 and PODXL expression in urothelial carcinoma of the urinary bladder. Prognostic and clinical implications. (PubMed, Contemp Oncol (Pozn))
    High RBM-HuR and PODXL expression and low expression of RBM3 were related to tumor recurrence (p = 0.022, 0.011 and 0.015). RBM-HuR and PODXL expressions are markers of poor prognosis while RBM3 is a good prognostic marker for urothelial carcinoma of the bladder.
    Journal
    |
    PODXL (Podocalyxin)
    |
    PODXL overexpression
    almost5years
    Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer. (PubMed, Sci Rep)
    A good response associates with podocalyxin negativity. A strong response associates with better outcome.
    Clinical • Journal
    |
    PODXL (Podocalyxin)
    |
    PODXL overexpression